JACC: ASIA © 2024 THE AUTHORS. PUBLISHED BY ELSEVIER ON BEHALF OF THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION. THIS IS AN OPEN ACCESS ARTICLE UNDER THE CC BY LICENSE (http://creativecommons.org/licenses/by/4.0/).

ORIGINAL RESEARCH

Bidirectional Associations Between Cardiometabolic Multimorbidity and Depression and Mediation of Lifestyles

A Multicohort Study

Yaguan Zhou, BMED,^{a,b} Mika Kivimäki, PHD,^c Carmen C.W. Lim, MSc,^{d,e} Rodrigo M. Carrillo-Larco, PHD,^{f,g} Shige Qi, MSC,^h Xifeng Wu, PHD,^{a,b} Xiaolin Xu, PHD^{a,b,i}

ABSTRACT

BACKGROUND Cardiometabolic multimorbidity (CMM) and depression are major health concerns, and the onset of either condition may heighten the risk of developing the other.

OBJECTIVES The goal of this study was to characterize the reciprocal associations between CMM and depression among middle-aged and older adults.

METHODS This multicohort study used harmonized data from 5 prospective cohorts from China, South Korea, the United States, the United Kingdom, and Europe. Cardiometabolic diseases (CMDs) (including diabetes, heart diseases, and stroke) and depression were assessed at baseline and at 7 to 8 years' follow-up. Lifestyle factors, including physical activity, alcohol consumption, and smoking status, were regarded as potential mediators. Two sets of analyses, CMM-depression analyses (n = 67,188) and depression-CMM analyses (n = 65,738), were conducted to explore the bidirectional associations between CMM and depression.

RESULTS In the CMM-depression analyses, 16,596 (24.7%) individuals developed depression. Participants with a single CMD (HR: 1.24; 95% CI:1.19-1.29) and CMM (HR: 1.52; 95% CI: 1.42-1.63) at baseline had higher risks of depression occurring. Physical activity and alcohol consumption significantly mediated 7.5% and 6.9% of the CMM-depression association, respectively. In the depression-CMM analyses, 1,461 (2.2%) participants developed CMM. The HR for developing CMM was 1.31 (95% CI: 1.14-1.50) in patients with depression, with increased risk of developing more CMDs. Physical activity and alcohol consumption mediated 12.0% and 7.1% of the depression-CMM association. The bidirectional relationships were more pronounced in Western countries than in Asian countries.

CONCLUSIONS CMM and depression were bidirectionally associated. The mediated effects of lifestyle factors were larger in the depression-lifestyle-CMM pathway than in the CMM-lifestyle-depression pathway. (JACC Asia. 2024;4:657-671) © 2024 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

From the ^aSchool of Public Health, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China; ^bThe Key Laboratory of Intelligent Preventive Medicine of Zhejiang Province, Hangzhou, Zhejiang, China; ^cUCL Brain Sciences, University College London, London, United Kingdom; ^dNational Centre for Youth Substance Use Research, Faculty of Health and Behavioral Sciences, The University of Queensland, Brisbane, Queensland, Australia; ^eSchool of Psychology, Faculty of Health and Behavioral Sciences, The University of Queensland, Brisbane, Queensland, Australia; ^fEmory Global Diabetes Research Center, Emory University, Atlanta, Georgia, USA; ^gHubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA; ^hNational Center for Chronic and Noncommunicable Disease Control and Prevention, Beijing, China; and the ⁱSchool of Public Health, Faculty of Medicine, The University of Queensland, Australia.

Kwang Kon Koh, MD, PhD, served as Guest Associate Editor for this paper. Nathan Wong, PhD, served as Guest Editor-in-Chief for this paper.

ABBREVIATIONS AND ACRONYMS

CMD = cardiometabolic disease

CMM = cardiometabolic multimorbidity

GEE = generalized estimating equation

RR = relative risk

epression, a common and debilitating psychiatric disorder, affects approximately 6% of the global population.^{1,2} In 2017, the World Health Organization listed depression as a leading cause of disability worldwide.³ In addition to its psychological impact, depression is often accompanied by somatic conditions⁴ such as dyslipidemia, rheumatoid arthritis, sleep disorders, and cardiometabolic diseases (CMDs), including diabetes, heart diseases, and stroke.⁵⁻⁷ Recent trends, including population aging, increased life expectancy, and lifestyle changes, have contributed to the accumulation of chronic conditions, leading to the increase in multimorbidity.⁸ In particular, there has been significant research interest in cardiometabolic multimorbidity (CMM), which is defined as the co-existence of two or more CMDs.9 CMM increases the risk of activity limitation, cognitive dysfunction, dementia, and all-cause mortality,^{10,11} presenting an ongoing challenge to global

health care systems. Recent research has provided evidence on the relationship between depression and CMDs. A prospective study with 27-year follow-up found that depression increased the risk of cardiometabolic health problems (eg, diabetes, erectile dysfunction, sleep apnea).¹² This finding was supported by two other cohort studies.^{13,14} The longitudinal association of CMDs with later depression has also been explored. For example, diabetes was found to be associated with increased risk of developing depression,¹⁵ and patients with stroke had a higher incidence of depression after hospitalization.¹⁶ However, these studies focused on single CMDs only, and, to the best of our knowledge, no current study has shed light directly on the reciprocal associations between depression and CMM. A population-based cohort study of 93,076 adults examined the bidirectional associations between depression and cardiovascular diseases (ischemic heart disease and stroke), but this study did not include diabetes and was exclusively conducted in Denmark, thus limiting the generalizability of its findings.17

CMM and depression are long-lasting and progressive, both of which could be partly attributable to modifiable indicators (eg, lifestyle factors).^{18,19} However, whether their bidirectional associations could be mediated by lifestyle factors remains unknown. To provide valuable insights for strategies to prevent and manage these significant physical and mental health challenges in the population,²⁰ we leveraged harmonized data across 19 countries from Asia, North America, and Europe to generate robust evidence on the bidirectional associations between CMM and depression and the mediation effects of lifestyle factors among middle-aged and older adults.

METHODS

STUDY DESIGN AND PARTICIPANTS. This prospective multicohort study adhered to the Strengthening the Reporting of Observational Studies in Epidemiology reporting guideline. Data were pooled across 19 countries from 5 sister cohort studies from the Program on Global Aging, Health and Policy²¹: CHARLS (China Health and Retirement Longitudinal Study); KLoSA (Korean Longitudinal Study of Aging); HRS (U.S. Health and Retirement Study); ELSA (English Longitudinal Study on Ageing); and SHARE (Survey of Health, Ageing and Retirement in Europe). These studies followed similar protocols and administered surveys every 2 or 3 years, therefore allowing meaningful cross-study comparisons. Additional details for each study have been described elsewhere.²²⁻²⁶

We used data from 4 waves of a consistent time period in each study, including waves 1 to 4 of CHARLS (2011-2019), waves 4 to 7 of KLoSA (2012-2019), waves 11 to 14 of HRS (2012-2019), waves 6 to 9 of ELSA (2012-2019), and waves 5 to 8 of SHARE (2013-2020) (Supplemental Table 1). In our analyses, we included participants if they were middle-aged and older adults (aged \geq 45 years) and reported complete information on CMDs and depression at baseline. Participants aged >85 years at baseline were excluded to minimize survival bias.

This study has been exempt from ethical review because it was a secondary analysis of a public data set.

CMDs AND CMM. The range of CMDs included selfreported diabetes, heart diseases, and stroke,²⁷ with definitions slight varied across studies. Heart diseases mainly referred to heart attack, coronary heart disease, angina, congestive heart failure, and other heart problems. The definition of stroke included ischemic attack in KLoSA and HRS; in ELSA and SHARE, it

Manuscript received January 3, 2024; revised manuscript received May 14, 2024, accepted June 13, 2024.

The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors' institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center.

included cerebrovascular diseases. CMM was identified as the coexistence of \geq 2 CMDs in an individual. In analyses of bidirectional associations, 2 variables were used: CMM status (no and yes) and CMD status (free of CMD, single CMD, and CMM). We additionally examined the number (0, 1, 2, and 3 CMDs) and combinations of CMDs, including the following groups: 1) none; 2) diabetes; 3) heart diseases; 4) stroke; 5) diabetes and heart diseases; 6) heart diseases and stroke; 7) diabetes and stroke; and 8) diabetes, heart diseases, and stroke.

DEPRESSION. In CHARLS and KLoSA, depression was assessed by using the 10-item version of the Center for Epidemiologic Studies Depression Scale. In HRS and ELSA, depression was assessed by using the 8-item version of the Center for Epidemiologic Studies Depression Scale. In SHARE, depression was assessed by using the 12-item version of the EURO-D. Individuals were then dichotomized into 2 groups of non-depression and depression using predefined study-specific cutoff values.²⁸⁻³² Detailed description of the assessment in each study is provided in Supplemental Table 2.

COVARIATES. Covariates, including demographic characteristics (age, sex, and study), socioeconomic status (marital status, educational level, and total household wealth), lifestyle factors (smoking status, drinking status, physical activity, and body mass index), history of chronic conditions (hypertension, cancer, and lung diseases), and medication of chronic conditions (hypertension and lung diseases) were assessed. Lifestyle factors and medication of chronic conditions were regarded as time-dependent variables, according to previous research and empirical evidence.³³ Total household wealth was calculated as the sum of all wealth components, including residence, business, vehicles, and savings account, excluding other debt or loans, and was categorized into quartiles. Further details of the measurement and harmonization of the covariates in each study are provided in Supplemental Table 2.

STATISTICAL ANALYSIS. The baseline characteristics of participants are described as number (percentage) according to CMD status and depression at baseline, and chi-square tests were used to compare the between-group differences. Two sets of analyses, CMM-depression analyses and depression-CMM analyses, were conducted to explore the bidirectional associations between CMM and depression.

CMM-Depression Analyses. Cox regression models with time-dependent covariates were used to estimate the HRs and 95% CIs of the association between baseline CMM and depression incidence during follow-up.

Participants were censored at interview month of depression or death, or end of follow-up of each cohort, whichever came first. Individuals were recorded as incident depression events if the depressive symptoms assessed by using study-specific instruments first appeared during follow-up. Considering the repeated measures on the same participants, we also applied generalized estimating equations (GEEs) for Poisson regression to estimate relative risks (RRs) and 95% CIs of the CMM-depression association. The mediation effects of lifestyles were further examined by using the mediation package in R (R Foundation for Statistical Computing). Physical activity, smoking status, and alcohol consumption were set as the mediators to estimate the total, indirect, and direct effects of CMM on depression, with the proportion mediated calculated via dividing indirect effect by total effect. Subgroup analyses were performed to compare the association of baseline CMM with incidence of depression among participants with different age (<65 years vs \geq 65 years), sex, educational level, total household income, and studies. Considering the heterogeneity across studies, we conducted meta-analyses using random-effects models to summarize study-specific estimates for the CMM-depression association among the whole sample and sex-stratified samples, with the betweenstudy heterogeneity tested using I^2 statistics. The multivariable logistic regression models were conducted to examine ORs and 95% CIs of the association between CMM at baseline and depression trajectory during follow-up, using a group-based trajectory model implemented with the PROC TRAJ procedure in SAS (Supplemental Methods).

Depression-CMM Analyses. Cox regression models with time-dependent covariates and the GEEs for Poisson regression were conducted to estimate HRs, RRs, and 95% CIs of the association between depression and CMM incidence. In the Cox regression models, participants were censored at interview month of CMM or death, or end of follow-up of each cohort, whichever came first. Individuals were recorded as incident CMM events if they reported to have CMM for the first time. Correspondingly, the mediation effects of lifestyles (physical activity, smoking status, and alcohol consumption) for the depression-CMM analyses were further examined. Subgroup analyses and metaanalyses using random-effects models for the association between depression and CMM incidence were also performed.

All tests in this study were 2-sided with a significance level of P < 0.05. Statistical analyses were conducted by using SAS version 9.4 (SAS Institute, Inc) and R version 4.2.2.

RESULTS

BASELINE CHARACTERISTICS. A total of 111,814 participants provided information on CMDs and depression at baseline. Participants already with depression at baseline (n = 28,773), lacking information on depression during follow-up (n = 13,274), or with missing information of covariates (n = 2,579)were excluded, yielding the final sample of 67,188 individuals for the CMM-depression analyses. The mean age of participants in the CMM-depression analyses was 64.36 \pm 9.22 years, and 35,243 (52.5%) were female. Of these, 7,228 participants were from China, 4,827 from South Korea, 12,635 participants were from the United States, and 42,498 from the United Kingdom and 15 other European countries (Figure 1, Supplemental Table 1). At baseline, 49,892 (74.3%) of 67,188 individuals did not have any CMDs, 14,082 (21.0%) had a single CMD, and 3,214 (4.8%) had CMM. Table 1 shows the baseline characteristics of participants in the CMM-depression analyses according to CMD status.

Similarly, for the depression-CMM analyses, this study excluded participants already with any CMDs at baseline (n = 32,437), lacking information on CMDs during follow-up (n = 10,786), or with missing information of covariates (n = 2,853), leaving 65,738 participants in the analyses. Their mean age was 63.02 ± 9.13 years, and 37,970(57.8%) were female. There were 9,708 individuals from China, 4,976 from South Korea, 9,980 individuals from the United States, and 41,074 from the United Kingdom, and 15 from other European countries (Figure 1, Supplemental Table 1). A total of 14,673 (22.3%) participants had depression at baseline; Table 2 shows the baseline characteristics of participants in the depression-CMM analyses according to depression status.

CMM-DEPRESSION ANALYSES: THE ASSOCIATION BETWEEN CMM AND INCIDENCE OF DEPRESSION. Of the 67,188 participants in the CMM-depression analyses, 16,596 (24.7%) progressed to depression during follow-up. Figure 2A displays the association between baseline CMM and depression incidence during follow-up using Cox regression models. Individuals with a single CMD (HR: 1.24; 95% CI: 1.19-1.29) and CMM (HR: 1.52; 95% CI: 1.42-1.63) at baseline had higher risks of developing depression. The risk of depression incidence rose as the number of baseline CMDs increased, with HRs ranging from 1.24 (95% CI: 1.19-1.29) to 1.60 (95% CI: 1.32-1.94). Those with combinations of diabetes, heart diseases, and stroke had the highest risk of developing depression (HR: 1.60; 95% CI: 1.32-1.94) (Central Illustration). Results from the GEE analyses also showed an increased risk of depression in those with a single CMD (RR: 1.34; 95% CI: 1.29-1.40) and CMM (RR: 1.78; 95% CI: 1.68-1.89), after adjusting for covariates (Supplemental Table 3).

The mediation effects of lifestyle factors on the association of CMM with depression are presented in Table 3. Physical activity and alcohol consumption positively mediated the CMM-depression association (mediation proportions of physical activity: 7.5%; of alcohol consumption: 6.9%), while smoking status had a negative mediation effect (mediation proportion: -2.3%). Subgroup analyses according to age, sex, educational level, and total household income yielded broadly similar results (Supplemental Tables 4 to 6). The CMM-depression association from Cox regression models were stronger in Western countries than in Asian countries (Figure 3A), with no sex differences observed (Supplemental Figures 1A to 1B). The pooled HRs for depression incidence were 1.23 (single CMD vs none; 95% CI: 1.15-1.31) and 1.54 (CMM vs none; 95% CI: 1.39-1.70), with mild between-study heterogeneity observed ($I^2 = 27\%-34\%$). The pooled RRs for depression incidence from GEE analyses showed no heterogeneity (Supplemental Figure 2A). Three trajectories for depression symptoms were identified: "persistently symptom-free," "persistently low," and "increasing" (Supplemental Table 7, Supplemental Figure 3). Increased risk for the "persistently low" and "increasing" depression trajectories were observed among those with CMM (Supplemental Table 8).

DEPRESSION-CMM ANALYSES: THE ASSOCIATION BETWEEN DEPRESSION AND INCIDENCE OF CMM. Of the 65,738 participants in the depression-CMM analyses, 10,082 (15.3%) participants developed a single CMD, and 1,461 (2.2%) developed CMM, including 103 (0.2%) with diabetes, heart diseases, and stroke. Figure 2B displays the association between baseline depression and incidence of CMM during follow-up using Cox regression models. Those with depression at baseline had higher risk of developing a single CMD (HR: 1.29; 95% CI: 1.22-1.36) and CMM (HR: 1.31; 95% CI: 1.14-1.50). Depression was associated with an elevated risk of developing more CMDs, although its association with 3 CMDs was imprecisely estimated. In addition, depression was significantly associated with specific combinations of CMDs (eg, HR: 1.30; 95% CI: 1.06-1.60 for diabetes and heart diseases) (Central Illustration). Results from GEE analyses yielded similar results, with RRs of 1.20 (95% CI: 1.14-1.26) and 1.53 (95% CI: 1.33-1.76) for



Participants were selected according to the inclusion and exclusion criteria, yielding 2 sample sets for the bidirectional analyses. CHARLS = China Health and Retirement Longitudinal Study; CMM = cardiometabolic multimorbidity; ELSA = English Longitudinal Study on Ageing; HRS = U.S. Health and Retirement Study; KLoSA = Korean Longitudinal Study of Aging; SHARE = Survey of Health, Ageing and Retirement in Europe.

TABLE 1 Baseline Characteris	stics of Participants Inc	luded in the CMM-Depr	ession Analyses Accor	ding to CMD Status		
			CMD Status at Baseline			
	Total (N = 67,188)	None (n = 49,892)	Single CMD (n = 14,082)	CMM (n = 3,214)	Chi-Square	P Value
Study					1,434.75	< 0.001
CHARLS	7,228 (10.8%)	6,195 (12.4%)	901 (6.4%)	132 (4.1%)		
KLoSA	4,827 (7.2%)	3,794 (7.6%)	890 (6.3%)	143 (4.4%)		
HRS	12,635 (18.8%)	8,045 (16.1%)	3,533 (25.1%)	1,057 (32.9%)		
ELSA	5,828 (8.7%)	4,361 (8.7%)	1,276 (9.1%)	191 (5.9%)		
SHARE	36,670 (54.6%)	27,497 (55.1%)	7,482 (53.1%)	1,691 (52.6%)		
Age, y					3,867.40	< 0.001
45-54	10,556 (15.7%)	9,374 (18.8%)	1,054 (7.5%)	128 (4.0%)		
55-64	25,054 (37.3%)	20,138 (40.4%)	4,175 (29.6%)	741 (23.1%)		
65-74	20,539 (30.6%)	14,080 (28.2%)	5,199 (36.9%)	1,260 (39.2%)		
≥75	11,039 (16.4%)	6,300 (12.6%)	3,654 (25.9%)	1,085 (33.8%)		
Sex					377.79	< 0.001
Male	31,945 (47.5%)	22,634 (45.4%)	7,506 (53.3%)	1,805 (56.2%)		
Female	35,243 (52.5%)	27,258 (54.6%)	6,576 (46.7%)	1,409 (43.8%)		
Education level					44.58	<0.001
Primary	22,926 (34.1%)	16,732 (33.5%)	4,955 (35.2%)	1,239 (38.6%)		
Secondary	26,127 (38.9%)	19,526 (39.1%)	5,409 (38.4%)	1,192 (37.1%)		
Tertiary	18,135 (27.0%)	13,634 (27.3%)	3,718 (26.4%)	783 (24.4%)		
Total household wealth ^a					621.61	< 0.001
Q1 (lowest)	16,281 (25.0%)	11,071 (23.0%)	4,085 (29.5%)	1,125 (35.3%)		
02	16.351 (25.1%)	11.910 (24.7%)	3.596 (26.0%)	845 (26.5%)		
03	16.295 (25.0%)	12.328 (25.6%)	3.287 (23.8%)	680 (21.3%)		
04 (highest)	16.306 (25.0%)	12.911 (26.8%)	2.859 (20.7%)	536 (16.8%)		
Marital status			,,		426.87	<0.001
Married or partnered	52,791 (78,6%)	39,903 (80,0%)	10.588 (75.2%)	2.300 (71.7%)		
Separated or divorced	5.035 (7.5%)	3.635 (7.3%)	1.138 (8.1%)	262 (8.2%)		
Widowed	6 846 (10 2%)	4 429 (8 9%)	1 883 (13 4%)	534 (16.6%)		
Never married	2 484 (3 7%)	1,129 (0.970)	466 (3.3%)	114 (3.6%)		
Physical activity	2,101 (5.770)	1,501 (5.070)	100 (5.570)	111 (3.070)	529 61	< 0.001
No	8 497 (13 4%)	5 528 (11 9%)	2 189 (16 1%)	780 (24.8%)	525.01	0.001
Vec	54 710 (86 6%)	40 958 (88 1%)	11 390 (83 9%)	2 362 (75 2%)		
Alcohol assumption	54,710 (00.070)	40,000 (00.170)	11,550 (05.570)	2,302 (73.270)	410 87	<0.001
Less than weekly drinking	36 399 (54 9%)	25 972 (52 8%)	8 264 (59 3%)	2 163 (67 8%)	+10.07	0.001
Wookly drinking or more	20,020 (45,1%)	23,372 (32.070)	6,207 (JJ.370)	1 025 (22 294)		
Current smaking	29,930 (43.1%)	23,223 (47.270)	5,082 (40.7%)	1,023 (32.2%)	167.49	<0.001
	EE 240 (92 40/)	40 EE0 (91 20/)	11 009 (95 30/)	2 702 (96 0%)	102.48	<0.001
No	11 024 (17 60/)	40,339 (81.3%)	2 094 (14 99/)	2,792 (00.9%)		
Pody mass index kg/m ²	11,034 (17.070)	9,329 (18.7%)	2,004 (14.8%)	421 (13.170)	2 208 05	<0.001
	059 (1 50/)	802 (1 70/)	142 (1 00/)	14 (0 40/)	2,208.95	0.001
< 18.5	958 (1.5%)	602 (1.7%)	142 (1.0%)	14 (0.4%)		
18.5-24.9	23,780 (36.5%)	19,602 (40.6%)	3,580 (26.2%)	598 (19.2%)		
25-29.9	25,525 (39.2%)	18,709 (38.7%)	5,013 (41.U%)	1,203 (38.6%)		
≥30.0	14,849 (22.8%)	9,206 (19.1%)	4,341 (31.7%)	1,302 (41.8%)	F 101 07	-0.001
Hypertension			5 350 (30 10/)	715 (22 20()	5,101.87	<0.001
	38,/12 (57.6%)	32,638 (65.4%)	5,359 (38.1%)	/15 (22.2%)		
Yes	28,460 (42.4%)	17,239 (34.6%)	8,722 (61.9%)	2,499 (77.8%)	212.50	0.001
Cancer					313.60	<0.001
No	61,867 (92.1%)	46,464 (93.1%)	12,607 (89.5%)	2,796 (87.0%)		
Yes	5,313 (7.9%)	3,424 (6.9%)	1,472 (10.5%)	417 (13.0%)		

Continued on the next page

developing a single CMD and CMM, respectively (Supplemental Table 3).

The mediation effects of lifestyle factors on the association of depression with CMM are presented in

Table 3. Physical activity and alcohol consumption mediated the depression-CMM association, with mediation proportions of 12.0% and 7.1% respectively, while the mediation effect of smoking status

TABLE 1 Continued						
			CMD Status at Baseline			
	Total (N = 67,188)	None (n = 49,892)	Single CMD (n = 14,082)	CMM (n = 3,214)	Chi-Square	P Value
Lung diseases					492.44	< 0.001
No	62,946 (93.7%)	47,291 (94.8%)	12,868 (91.4%)	2,787 (86.7%)		
Yes	4,233 (6.3%)	2,595 (5.2%)	1,212 (8.6%)	426 (13.3%)		
Medication for hypertension					4,879.99	< 0.001
No	42,787 (63.8%)	35,456 (71.2%)	6,393 (45.5%)	938 (29.3%)		
Yes	24,233 (36.2%)	14,314 (28.8%)	7,657 (54.5%)	2,262 (70.7%)		
Medication for lung disease					231.69	< 0.001
No	65,584 (97.7%)	48,955 (98.2%)	13,582 (96.6%)	3,047 (95.0%)		
Yes	1,552 (2.3%)	909 (1.8%)	484 (3.4%)	159 (5.0%)		

Values are n (%) unless otherwise indicated. ^aTotal household wealth was categorized into quartiles.

CHARLS = China Health and Retirement Longitudinal Study; CMD = cardiometabolic disease; CMM = cardiometabolic multimorbidity; ELSA = English Longitudinal Study on Ageing; HRS = U.S. Health and Retirement Study; KLoSA = Korean Longitudinal Study of Aging; Q = quartile; SHARE = Survey of Health, Ageing and Retirement in Europe.

was nonsignificant. The subgroups analyses showed that age, sex, educational level, and total household income did not substantially modify the depression-CMM association (Supplemental Tables 9 to 11). However, study-specific HRs indicated that the depression-CMM association attenuated to nonsignificance in Asian countries (eg, in CHARLS, HR for CMM: 1.10; 95% CI: 0.52-2.30) (Figure 3B), showing similar patterns between the sexes (Supplemental Figures 1C to 1D). The pooled HR was 1.32 (95% CI: 1.08-1.62: $I^2 = 79\%$) for developing a single CMD and 1.31 (95% CI: 1.14-1.51; $I^2 = 0\%$) for developing CMM among those with baseline depression (Figure 3B). The meta-analyses from GEEs for Poisson regression models also generated significant results (RR of developing a single CMD: 1.18 [95% CI: 1.12-1.25]; RR of developing CMM: 1.51 [95% CI: 1.31-1.74]), with between-study heterogeneity of 0% to 22% (Supplemental Figure 2B).

DISCUSSION

In this study involving 5 aging cohorts across 19 countries from Asia, North America, and Europe, bidirectional associations between CMM and depression were found. Individuals with a single CMD and CMM at baseline had an elevated risk of developing depression. Alcohol consumption and physical activity significantly mediated a proportion of 6.9% to 7.5% of the association of CMM with depression. Similarly, individuals with depression had an increased risk of developing CMM, which rose with the number of CMDs, though this association was imprecise in some analyses. The mediation proportion of alcohol consumption and physical activity was 7.1% to 12.0% for the depression-CMM association.

Although the association between CMDs and depression has been widely explored in prior research,^{12,34,35} little attention has been paid to the longitudinal impact of CMM on the incidence of depression. Our study addressed this knowledge gap and found that individuals with CMM, regardless of specific CMD combinations, experienced a heightened risk of developing depression. Considering that the variables were collected over time as repeated measures, we further conducted GEEs for Poisson regression to longitudinally estimate the CMMdepression association, the results of which suggest that the longitudinal association of CMM with depression is robust. Our meta-analyses and additional analyses examining depression trajectories during follow-up showed a similar pattern of results, with no significant between-study heterogeneity.

We also observed a longitudinal association between depression and subsequent CMM from both Cox regression models with time-dependent covariates and GEE analyses. This finding concurs with a cohort study based on the UK Biobank¹⁴ but that study included only UK participants, limiting the generalization of its results. By using a broader range of nationally representative samples from 19 countries, our study confirmed the relationship between depression and CMM incidence, although the HRs for some categories of CMM were imprecisely estimated (eg, CMM of 3 CMDs), probably owing to the small participant numbers in these categories. In our metaanalyses, the main associations between depression and CMM incidence were significant but with significant between-study heterogeneity. The studyspecific HRs suggested that the longitudinal association between depression and CMM incidence might

TABLE 2 Baseline Characteristic	cs of Participants Includ	led in the Depression-CMN	Analyses According to	Depression Status		
		Depression	at Baseline			
	Total	No	Yes			
	(N = 65,738)	(n = 51,065)	(n = 14,673)	Chi-Square	P Value	
Study				648.37	< 0.001	
CHARLS	9,708 (14.8%)	6,348 (12.4%)	3,360 (22.9%)			
KLoSA	4,976 (7.6%)	3,794 (7.4%)	1,182 (8.1%)			
HRS	9,980 (15.2%)	8,146 (16.0%)	1,834 (12.5%)			
ELSA	4,884 (7.4%)	4,392 (8.6%)	492 (3.4%)			
SHARE	36,190 (55.1%)	28,385 (55.6%)	7,805 (53.2%)			
Age, y				62.45	< 0.001	
45-54	12,753 (19.4%)	9,623 (18.8%)	3,130 (21.3%)			
55-64	26,274 (40.0%)	20,574 (40.3%)	5,700 (38.8%)			
65-74	18,017 (27.4%)	14,376 (28.2%)	36,41 (24.8%)			
≥75	8,694 (13.2%)	6,492 (12.7%)	2,202 (15.0%)			
Sex				535.75	< 0.001	
Male	27,768 (42,2%)	23,211 (45,5%)	4.557 (31.1%)			
Female	37 970 (57 8%)	27 854 (54 5%)	10 116 (68 9%)			
Education level	51,576 (51,676)	27,001 (011070)		660 38	< 0.001	
Brimany	24 560 (37 4%)	17 227 (22 8%)	7 332 (50 0%)	000.50	<0.001	
Secondary	24,303 (37.470)	10,017 (20,0%)	4 946 (22 0%)			
Secolulary	24,703 (37.7%)	19,917 (39.0%)	4,846 (33.0%)			
Tettal bases bald suggitted	16,406 (25.0%)	13,911 (27.2%)	2,495 (17.0%)	622.52	-0.001	
otal nousenoid wealth	15 704 (24 00()	11 050 (22 49/)	4 706 (00 00()	632.53	<0.001	
QI (lowest)	15,/84 (24.9%)	11,058 (22.4%)	4,726 (33.9%)			
Q2	15,829 (25.0%)	12,205 (24.7%)	3,624 (26.0%)			
Q3	15,857 (25.1%)	12,750 (25.8%)	3,107 (22.3%)			
Q4 (highest)	15,830 (25.0%)	13,355 (27.1%)	2,475 (17.8%)			
Marital status				337.07	<0.001	
Married or partnered	51,339 (78.1%)	40,837 (80.0%)	10,502 (71.6%)			
Separated or divorced	5,046 (7.7%)	3,700 (7.2%)	1,346 (9.2%)			
Widowed	6,748 (10.3%)	4,548 (8.9%)	2,200 (15.0%)			
Never married	2,580 (3.9%)	1,958 (3.8%)	622 (4.2%)			
Physical activity				398.46	< 0.001	
No	8,432 (14.0%)	5,649 (11.9%)	2,783 (21.7%)			
Yes	51,955 (86.0%)	41,937 (88.1%)	10,018 (78.3%)			
Alcohol assumption				409.26	<0.001	
Less than weekly drinking	36,275 (56.0%)	26,651 (52.9%)	9,624 (66.5%)			
Weekly drinking or more	28,555 (44.0%)	23,710 (47.1%)	4,845 (33.5%)			
Current smoking				119.01	<0.001	
No	52,656 (80.1%)	41,448 (81.2%)	11,208 (76.4%)			
Yes	13.076 (19.9%)	9.613 (18.8%)	3.463 (23.6%)			
Body mass index kg/m ²				145 18	< 0.001	
<18.5	1 358 (2 1%)	824 (17%)	534 (3.8%)			
18 5-24 9	26 247 (41 3%)	20 109 (40 7%)	6 138 (43 8%)			
25-29.9	23,211 (37,5%)	10 158 (38 7%)	4 653 (33 2%)			
>20.0	12 074 (10 0%)	0 277 (10 0%)	2,607 (10,2%)			
	12,074 (19.070)	9,377 (19.070)	2,037 (13.270)	27.15	<0.001	
No	42 542 (64 70/)	22 417 (65 50/)	0 125 (62 20/)	57.15	<0.001	
NO	42,542 (64.7%)	33,417 (05.5%)	9,125 (62.2%)			
Yes	23,166 (35.3%)	17,632 (34.5%)	5,534 (37.8%)	0.53	0.001	
Cancer				9.53	<0.001	
No	61,119 (93.0%)	47,578 (93.2%)	13,541 (92.3%)			
Yes	4,610 (7.0%)	3,483 (6.8%)	1,127 (7.7%)			
Lung diseases				193.41	<0.001	
No	61,636 (93.8%)	48,406 (94.8%)	13,230 (90.2%)			
Yes	4,095 (6.2%)	2,653 (5.2%)	1,442 (9.8%)			
Medication for hypertension				9.73	0.001	
No	46,536 (71.0%)	36,307 (71.3%)	10,229 (69.9%)			
Yes	19,042 (29.0%)	14,631 (28.7%)	4,411 (30.1%)			
Medication for lung disease				103.10	< 0.001	
No	64,204 (97.7%)	50,107 (98.2%)	14,097 (96.1%)			
Yes	1,498 (2.3%)	929 (1.8%)	569 (3.9%)			

Values are n (%). ^aTotal household wealth was categorized into quartiles. Abbreviations as in Table 1.

RE 2 Associations Between CMM and Depre	ession		
Α			
	Cases/n	HR (95% CI)	
CMM status \rightarrow depression			
No	15503/63974	1.00 (REF)	+
Yes	1093/3214	1.40 (1.31–1.50)	-
CMD status \rightarrow depression			
Free of CMD	11530/49892	1.00 (REF)	+
Single CMD	3973/14082	1.24 (1.19-1.29)	-
СММ	1093/3214	1.52 (1.42-1.63)	-
Number of CMDs \rightarrow depression			
0	11530/49892	1.00 (REF)	+
1	3973/14082	1.24 (1.19-1.29)	-
2	980/2902	1.51 (1.41-1.62)	-
3	113/312	1.60 (1.32-1.94)	
CMD combinations \rightarrow depression			
None	11530/49892	1.00 (REF)	+
Diabetes only	1725/6309	1.20 (1.13-1.26)	-
Heart diseases only	1824/6361	1.26 (1.19-1.33)	-
Stroke only	424/1412	1.31 (1.19-1.46)	-
Diabetes and heart diseases	611/1841	1.50 (1.37-1.64)	-
Diabetes and stroke	137/391	1.58 (1.32-1.89)	
Heart diseases and stroke	232/670	1.50 (1.31-1.72)	
Diabetes, heart diseases and stroke	113/312	1.60 (1.32-1.94)	_
			0 1 2
В			
2	Cases/n	HR (95% CI)	
Depression \rightarrow CMM status			
No	14219/14673	1.00 (REF)	÷
Yes	454/14673	1.25 (1.09-1.43)	
Depression \rightarrow CMD status			
Free of CMD	11447/14673	1.00 (REF)	+
Single CMD	2772/146732	1.29 (1.22-1.36)	•
СММ	454/14673	1.31 (1.14-1.50)	
Depression \rightarrow Number of CMDs		,	
0	11447/14673	1.00 (REF)	Ļ
1	2772/146732	1.29 (1.22-1.36)	•
2	414/14673	1.31 (1.14–1.51)	
3	40/14673	1.23 (0.70-2.17)	_
Depression → CMD combinations		,	
None		1.00 (REE)	Ļ
	11447/14673		
Diabetes only	11447/14673 956/14673	1.22 (1.12-1.33)	-
Diabetes only Heart diseases only	11447/14673 956/14673 1391/14673	1.22 (1.12–1.33) 1.38 (1.28–1.48)	+ +
Diabetes only Heart diseases only Stroke only	1144//14673 956/14673 1391/14673 425/14673	1.22 (1.12–1.33) 1.38 (1.28–1.48) 1.32 (1.16–1.51)	+ + +
Diabetes only Heart diseases only Stroke only Diabetes and heart diseases	1144//14673 956/14673 1391/14673 425/14673 209/14673	1.22 (1.12–1.33) 1.38 (1.28–1.48) 1.32 (1.16–1.51) 1.30 (1.06–1.60)	* * *
Diabetes only Heart diseases only Stroke only Diabetes and heart diseases Diabetes and stroke	1144//14673 956/14673 1391/14673 425/14673 209/14673 64/14673	1.22 (1.12-1.33) 1.38 (1.28-1.48) 1.32 (1.16-1.51) 1.30 (1.06-1.60) 1.44 (0.98-2.11)	* * * -
Diabetes only Heart diseases only Stroke only Diabetes and heart diseases Diabetes and stroke Heart diseases and stroke	1144//146/3 956/14673 1391/14673 425/14673 209/14673 64/14673 141/14673	1.22 (1.12-1.33) 1.38 (1.28-1.48) 1.32 (1.16-1.51) 1.30 (1.06-1.60) 1.44 (0.98-2.11) 1.28 (1.02-1.61)	* * * -*
Diabetes only Heart diseases only Stroke only Diabetes and heart diseases Diabetes and stroke Heart diseases and stroke Diabetes heart diseases and stroke	1144//14673 956/14673 1391/14673 425/14673 209/14673 64/14673 141/14673 40/14673	1.30 (1.21 - 1.33) 1.32 (1.12-1.33) 1.38 (1.28-1.48) 1.32 (1.16-1.51) 1.30 (1.06-1.60) 1.44 (0.98-2.11) 1.28 (1.02-1.61) 1.23 (0.70-2.17)	
Diabetes only Heart diseases only Stroke only Diabetes and heart diseases Diabetes and stroke Heart diseases and stroke Diabetes, heart diseases and stroke	1144//14673 956/14673 1391/14673 425/14673 209/14673 64/14673 141/14673 40/14673	1.22 (1.12-1.33) 1.38 (1.28-1.48) 1.32 (1.16-1.51) 1.30 (1.06-1.60) 1.44 (0.98-2.11) 1.28 (1.02-1.61) 1.23 (0.70-2.17)	

The forest plots show the HRs and 95% CIs for the cardiometabolic multimorbidity (CMM)-depression analyses (A) and the depression-CMM analyses (B) generated by Cox regression models with time-dependent covariates. Models were adjusted for age, sex, and study, marital status, educational level, and total household wealth, smoking status, drinking status, physical activity, body mass index (BMI), history of hypertension, cancer, and lung diseases, and medication of hypertension and lung diseases. CMD = cardiometabolic disease.



Participants aged \geq 45 years from 5 cohorts in Asian and Western countries were included to evaluate the bidirectional associations between cardiometabolic multimorbidity (CMM) and depression, and the mediation effects of lifestyles. CHARLS = China Health and Retirement Longitudinal Study; CMD = cardiometabolic disease; ELSA = English Longitudinal Study on Ageing; HRS = the U.S. Health and Retirement Study; KLoSA = Korean Longitudinal Study of Aging; SHARE = Survey of Health, Ageing and Retirement in Europe.

667

	Direct Effect		Indirect Effect		
	Coefficients (95% CI)	P Value	Coefficients (95% CI)	P Value	% Mediated
CMM-depression analyses					
CMD status \rightarrow depression					
Physical activity	4.13 (2.86-5.41)	<0.001	0.34 (0.25-0.43)	<0.001	7.5
Smoking status	4.14 (2.18-6.24)	<0.001	-0.10 (-0.18 to -0.03)	0.006	-2.3
Alcohol consumption	4.39 (3.08-5.66)	<0.001	0.32 (0.24-0.42)	<0.001	6.9
Depression-CMM analyses					
Depression \rightarrow single CMD					
Physical activity	7.13 (5.40-8.93)	<0.001	0.30 (0.18-0.44)	<0.001	4.0
Smoking status	7.37 (5.51-9.12)	<0.001	0.01 (-0.05 to 0.08)	0.77	1.1
Alcohol consumption	7.04 (5.53-8.61)	<0.001	0.25 (0.16-0.35)	<0.001	3.5
Depression \rightarrow CMM					
Physical activity	2.50 (-1.43 to 6.64)	<0.001	0.40 (0.14-0.65)	<0.001	12.0
Smoking status	4.38 (1.49-7.18)	<0.001	-0.06 (-0.20 to 0.05)	0.29	-1.4
Alcohol consumption	4.06 (1.20-6.98)	0.006	0.31 (0.15-0.48)	<0.001	7.1

Models were adjusted for age, sex, study, marital status, educational level, total household wealth, body mass index (BMI), history of hypertension, cancer and lung diseases, and medication of hypertension and lung diseases.

Abbreviations as in Table 1.

be more pronounced in Western countries than in Asian countries, stressing the importance of considering large-sample populations with different cultural contexts in future research. However, the meta-analyses using random-effects models from GEEs observed nonsignificant between-study heterogeneity.

Our findings further included 3 lifestyle factors and found the bidirectional associations between CMM and depression were positively mediated by physical activity and alcohol consumption, suggesting that targeted interventions limiting drinking and improving physical activity would be more effective. Smoking status was found to negatively mediate the CMM-depression association, which might be explained by the short follow-ups and reverse causality. In addition, larger mediated proportions of lifestyle factors were observed in the depression-CMM pathway than otherwise, suggesting that lifestyle interventions might be more effective to prevent or delay CMM onset among individuals with depression.

Our findings are biologically plausible. The observed associations of stroke, heart diseases, and diabetes with elevated depression incidence in this study are consistent with at least 3 mechanistic hypotheses: the poststroke depression hypothesis, the vascular depression hypothesis,³⁶ and the diabetes-depression hypothesis.^{37,38} Poststroke depression refers to depression that occurs in the context of a

clinically apparent stroke³⁶ and might be related to inflammatory processes, hypothalamic-pituitaryadrenal axis abnormalities, and alterations in neuroplasticity and glutamate neurotransmission.³⁹ Vascular depression, in turn, refers to depression in the presence of vascular risk factors accompanied by neuropsychological deficit and distinct localized brain pathology.³⁶ The longitudinal association between diabetes and depression might be driven by vascular and metabolic pathology.⁴⁰ Microvascular dysfunction is common in people with diabetes, including effects on the brain, and its diabetesrelated drivers are hyperglycemia, obesity and insulin resistance, and hypertension.^{37,38}

There are also several plausible mechanisms for the effects of depression on CMDs, although the evidence is less robust. The depression-CMD association might be explained by depression-related alterations in the autonomic nervous system, platelet receptors and function, coagulopathic factors, proinflammatory cytokines, and neurohormonal factors.⁴¹ Chronic stress, a correlate of depression, increases the production of cortisol in the adrenal cortex and activates the sympathetic nervous system,^{42,43} while hypercortisolemia and sympathetic nervous system activation further contribute to insulin resistance, diabetes, and metabolic syndrome.44 Hypercortisolemia can induce tachyphylaxis of the reward system and the disturbed neurogenesis in the hippocampus, both related to depression.45,46

Study	β	SE	Hazard Ratio	Cases/n	95%CI	Weig
Single CMD (vs. none)) → Depr	ression	1			
CHARLS	0.04	0.1087	+	386/901	1.04 (0.84-1.28)	15.3
KLoSA	0.13	0.0661	-	322/890	1.14 (1.00-1.29)	20.3
HRS	0.23	0.0442	*	895/3533	1.26 (1.15-1.37)	22.7
ELSA	0.24	0.0897		223/1276	1.28 (1.07-1.52)	17.5
SHARE	0.25	0.0271		2147/7482	1.28 (1.22-1.35)	24.1
Random effects mode	2		\$		1.23 (1.15-1.31)	100.0
Heterogeneity: $I^2 = 34\%$,	p = 0.19					
CMM (vs. none) → De	pression					
CHARLS	0.12	0.2581		66/132	1.13 (0.68-1.87)	7.79
KLoSA	0.37	0.1321		65/143	1.45 (1.12-1.88)	18.2
HRS	0.37	0.0667	-	302/1057	1.44 (1.26-1.64)	28.4
ELSA	0.66	0.1673		53/191	1.94 (1.40-2.69)	14.1
SHARE	0.48	0.0457	-	607/1691	1.61 (1.47-1.76)	31.6
Random effects mode	2 1		\$		1.54 (1.39-1.70)	100.0
Heterogeneity: / ² = 27%,	p = 0.24					
В			0.1 0.2 0.5 1 2	5 10		
B Study	β	SE	Hazard Ratio	5 10 Cases/n	95%CI	Weig
B Study	β	SE	Hazard Ratio	5 10 Cases/n	95%CI	Weig
B Study Depression (vs. none)	β) → Singl	SE e CMD	Hazard Ratio	5 10 Cases/n	95%CI	Weig
B Study Depression (vs. none) CHARLS	β) → Singl 0.20	SE 0.0883 0.1079	Hazard Ratio	5 10 Cases/n 819/3360 121/1182	95%CI 1.22 (1.03-1.46)	Weig
B Study Depression (vs. none) CHARLS KLOSA	β) → Singl 0.20 0.02 0.25	SE 0.0883 0.1079	Hazard Ratio	5 10 Cases/n 819/3360 131/1182 296/1824	95%CI 1.22 (1.03-1.46) 1.02 (0.82-1.26) 1.29 (1.14.1.45)	Weig 19.2 17.0
B Study Depression (vs. none) CHARLS KLOSA HRS ELSA	β 0.20 0.25 0.68	SE 0.0883 0.1079 0.0608 0.1134	Hazard Ratio	5 10 Cases/n 819/3360 131/1182 396/1834 118/492	95%Cl 1.22 (1.03-1.46) 1.02 (0.82-1.26) 1.29 (1.14-1.45) 1.27 (1.58-2.46)	Weig 19.2 17.0 22.3
B Study Depression (vs. none) CHARLS KLoSA HRS ELSA SHARE	β 0.20 0.22 0.25 0.68 0.26	SE 0.0883 0.1079 0.0608 0.1134 0.0200	Hazard Ratio	5 10 Cases/n 819/3360 131/1182 396/1834 118/492 1309/7805	95%Cl 1.22 (1.03-1.46) 1.02 (0.82-1.26) 1.29 (1.14-1.45) 1.97 (1.58-2.46) 1.20 (1.23 1.28)	Weig 19.2 17.0 22.3 16.4
B Study Depression (vs. none) CHARLS KLoSA HRS ELSA SHARE Bandom offects mode	β 0.20 0.02 0.25 0.68 0.26	SE 0.0883 0.1079 0.0608 0.1134 0.0300	Hazard Ratio	5 10 Cases/n 819/3360 131/1182 396/1834 118/492 1308/7805	95%Cl 1.22 (1.03-1.46) 1.02 (0.82-1.26) 1.29 (1.14-1.45) 1.97 (1.58-2.46) 1.30 (1.23-1.38) 1.32 (1.08, 1 62)	Weig 19.2 17.0 22.3 16.4 25.1
B Study Depression (vs. none) CHARLS KLoSA HRS ELSA SHARE Random effects mode Heterogeneity: / ² = 79%, /	β 0.20 0.22 0.25 0.68 0.26 !] p < 0.01	SE 0.0883 0.1079 0.0608 0.1134 0.0300	Hazard Ratio	5 10 Cases/n 819/3360 131/1182 396/1834 118/492 1308/7805	95%Cl 1.22 (1.03-1.46) 1.02 (0.82-1.26) 1.29 (1.14-1.45) 1.97 (1.58-2.46) 1.30 (1.23-1.38) 1.32 (1.08-1.62)	Weig 19.2 17.0 22.3 16.4 25.1 100.0
B Study Depression (vs. none) CHARLS KLoSA HRS ELSA SHARE Random effects mode Heterogeneity: / ² = 79%, Depression (vs. none)	β) → Singl 0.20 0.02 0.25 0.68 0.26 1 <i>p</i> < 0.01	SE 0.0883 0.1079 0.0608 0.1134 0.0300	Hazard Ratio	5 10 Cases/n 819/3360 131/1182 396/1834 118/492 1308/7805	95%CI 1.22 (1.03-1.46) 1.02 (0.82-1.26) 1.29 (1.14-1.45) 1.97 (1.58-2.46) 1.30 (1.23-1.38) 1.32 (1.08-1.62)	Weig 19.2 17.0 22.3 16.4 25.1 100.0
B Study Depression (vs. none) CHARLS KLoSA HRS ELSA SHARE Random effects mode Heterogeneity: / ² = 79%, Depression (vs. none) CHARLS	β) → Singl 0.20 0.25 0.68 0.26 1 p < 0.01) → CMM 0.13	SE 0.0883 0.1079 0.0608 0.1134 0.0300	Hazard Ratio	5 10 Cases/n 819/3360 131/1182 396/1834 118/492 1308/7805	95%CI 1.22 (1.03-1.46) 1.02 (0.82-1.26) 1.29 (1.14-1.45) 1.97 (1.58-2.46) 1.30 (1.23-1.38) 1.32 (1.08-1.62) 1.14 (0.81-1.62)	Weig 19.2 17.0 22.3 16.4 25.1 100.0
B Study Depression (vs. none) CHARLS KLoSA HRS ELSA SHARE Random effects mode Heterogeneity: / ² = 79%, , Depression (vs. none) CHARLS KLoSA	β) → Singl 0.20 0.25 0.68 0.26 p < 0.01) → CMM 0.13 0.10	SE 0.0883 0.1079 0.0608 0.1134 0.0300 0.1791 0.3775	0.1 0.2 0.5 1 2 Hazard Ratio	5 10 Cases/n 819/3360 131/1182 396/1834 118/492 1308/7805 189/3360 12/1182	95%CI 1.22 (1.03-1.46) 1.02 (0.82-1.26) 1.29 (1.14-1.45) 1.97 (1.58-2.46) 1.30 (1.23-1.38) 1.32 (1.08-1.62) 1.14 (0.81-1.62) 1.10 (0.52-2.30)	Weig 19.2 17.0 22.3 16.4 25.1 100. 0 22.2 7.3
B Study Depression (vs. none) CHARLS KLoSA HRS ELSA SHARE Random effects mode Heterogeneity: / ² = 79%, / Depression (vs. none) CHARLS KLoSA HRS	β 0.20 0.25 0.26 0.26 0.26 0.26 0.26 0.26 0.26 0.26	SE 0.0883 0.1079 0.0608 0.1134 0.0300 0.1791 0.3775 0.1668	0.1 0.2 0.5 1 2 Hazard Ratio	5 10 Cases/n 819/3360 131/1182 396/1834 118/492 1308/7805 189/3360 12/1182 56/1834	95%Cl 1.22 (1.03-1.46) 1.02 (0.82-1.26) 1.29 (1.14-1.45) 1.97 (1.58-2.46) 1.30 (1.23-1.38) 1.32 (1.08-1.62) 1.14 (0.81-1.62) 1.10 (0.52-2.30) 1.40 (1.01-1.94)	Weig 19.2 17.0 22.3 16.4 25.1 100. 0 22.2 7.3° 24.1
B Study Depression (vs. none) CHARLS KLoSA HRS ELSA SHARE Random effects mode Heterogeneity: / ² = 79%, Depression (vs. none) CHARLS KLoSA HRS ELSA	β) → Singl 0.20 0.25 0.68 0.26 1 p < 0.01) → CMM 0.13 0.10 0.33 0.79	SE 0.0883 0.1079 0.0608 0.1134 0.0300 0.1791 0.3775 0.1668 0.4008	0.1 0.2 0.5 1 2 Hazard Ratio	5 10 Cases/n 819/3360 131/1182 396/1834 118/492 1308/7805 189/3360 12/1182 56/1834 - 8/492	95%Cl 1.22 (1.03-1.46) 1.02 (0.82-1.26) 1.29 (1.14-1.45) 1.97 (1.58-2.46) 1.30 (1.23-1.38) 1.32 (1.08-1.62) 1.14 (0.81-1.62) 1.10 (0.52-2.30) 1.40 (1.01-1.94) 2.0 (1 00-4 83)	Weig 19.2 17.0 22.3 16.4 25.1 100.0 22.2 7.3 24.1 6 5 ⁵
B Study Depression (vs. none) CHARLS KLoSA HRS ELSA SHARE Random effects mode Heterogeneity: / ² = 79%, , Depression (vs. none) CHARLS KLoSA HRS ELSA SHARE	β) → Singl 0.20 0.02 0.25 0.68 0.26 ⊮ p < 0.01) → CMM 0.13 0.10 0.33 0.79 0.27	SE 0.0883 0.1079 0.0608 0.1134 0.0300 0.1791 0.3775 0.1668 0.4008 0.0916	Hazard Ratio	5 10 Cases/n 819/3360 131/1182 396/1834 118/492 1308/7805 189/3360 12/1182 56/1834 - 8/492 189/7305	95%Cl 1.22 (1.03-1.46) 1.02 (0.82-1.26) 1.29 (1.14-1.45) 1.97 (1.58-2.46) 1.30 (1.23-1.38) 1.32 (1.08-1.62) 1.10 (0.52-2.30) 1.40 (1.01-1.94) 2.20 (1.00-4.83) 1.31 (1 10-1.57)	Weig 19.2 17.0 22.3 16.4 25.1 100.0 22.2 7.3° 24.1 6.5° 39.9
B Study Depression (vs. none) CHARLS KLoSA HRS ELSA SHARE Random effects mode Heterogeneity: / ² = 79%, / Depression (vs. none) CHARLS KLoSA HRS ELSA SHARE Random effects mode	β) → Singl 0.20 0.02 0.25 0.68 0.26 1 p < 0.01) → CMM 0.13 0.10 0.33 0.79 0.27	SE 0.0883 0.1079 0.0608 0.1134 0.0300 0.1791 0.3775 0.1668 0.4008 0.0916	Hazard Ratio	5 10 Cases/n 819/3360 131/1182 396/1834 118/492 1308/7805 189/3360 12/1182 56/1834 8/492 189/7305	95%CI 1.22 (1.03-1.46) 1.02 (0.82-1.26) 1.29 (1.14-1.45) 1.97 (1.58-2.46) 1.30 (1.23-1.38) 1.32 (1.08-1.62) 1.14 (0.81-1.62) 1.10 (0.52-2.30) 1.40 (1.01-1.94) 2.20 (1.00-4.83) 1.31 (1.10-1.57) 1.31 (1 14-1 51)	Weig 19.2 17.0 22.3 16.4 25.1 100.0 22.2 7.3 24.1 6.5 39.9 100 .0
B Study Depression (vs. none) CHARLS KLoSA HRS ELSA SHARE Random effects mode Heterogeneity: / ² = 79%, / Depression (vs. none) CHARLS KLoSA HRS ELSA SHARE Random effects mode Heterogeneity: / ² = 0% o	β) → Singl 0.20 0.25 0.68 0.26 1 p < 0.01) → CMM 0.13 0.10 0.33 0.79 0.27 1 = 0.63	SE 0.0883 0.1079 0.0608 0.1134 0.0300 0.1791 0.3775 0.1668 0.4008 0.0916	Hazard Ratio	5 10 Cases/n 819/3360 131/1182 396/1834 118/492 1308/7805 189/3360 12/1182 56/1834 8/492 189/7305	95%CI 1.22 (1.03-1.46) 1.02 (0.82-1.26) 1.29 (1.14-1.45) 1.97 (1.58-2.46) 1.30 (1.23-1.38) 1.32 (1.08-1.62) 1.14 (0.81-1.62) 1.10 (0.52-2.30) 1.40 (1.01-1.94) 2.20 (1.00-4.83) 1.31 (1.10-1.57) 1.31 (1.14-1.51)	Weig 19.2 17.C 22.3 16.4 25.1 100 .0 22.2 7.3 24.1 6.5 ⁵ 39.9 100 .0

Random-effects meta-analyses were conducted to calculate the HRs and 95% CIs for CMM-depression analyses (A) and depression analyses (B). Heterogeneity was tested by using l^2 statistics. Abbreviations as in Figures 1 and 2.

Our research has important implications for clinical practice and public health policy. The evidence highlights the likelihood of shared pathways between physical and mental conditions, suggesting that preventive interventions should commence early.⁴⁷ Health care providers should be attentive to the heightened risk of depression in patients with CMM and implement timely interventions to safeguard their mental well-being. Similarly, there may be a

need to enhance CMM prevention measures when treating patients with depression to prevent a cycle in which mental and physical health issues exacerbate each other. In summary, prioritizing integrated, person-centered care that addresses both CMM and depression is essential. This approach can help alleviate the burden of these conditions, enhance physical and mental health, and mitigate adverse health outcomes during middle and old age.

STUDY LIMITATIONS. First, the information of CMM, including diabetes, heart diseases, and stroke, was self-reported, and this was subject to recall bias. However, previous studies have shown that selfreported CMDs have good credibility.48-51 Second, the included participants were from high-income countries or upper-middle income countries. Whether the bidirectional associations between CMM and depression apply to populations from lowermiddle and low-income countries warrants further investigation. Third, the information of CMM symptoms and severity, and the diagnosis, medication, and subtypes of depression were unavailable, which could influence observed associations. Last, we included 4 waves of each cohort with only 8-year follow-up to capture the information of exposures and outcomes, which is subject to reverse causality effects. Therefore, future population-based studies with long-term follow-up are needed. Finally, because of data availability limitations and population differences among the included cohorts, measurement of depressive symptoms relied on study-specific multi-item instruments, rather than the same measures across all cohorts. Although we used predefined cutoffs for defining caseness, and all instruments were validated,⁵²⁻⁵⁵ the variations in measurement tools across cohorts may have contributed to increased heterogeneity in cohort-specific results. Ideally, future research should use similar protocols and consistent cutoff thresholds across all included cohorts to confirm the validity of the findings.^{56,57}

CONCLUSIONS

CMM and depression showed bidirectional associations, with the onset of either condition significantly increasing the risk of developing the other. Our findings underscore the importance of holistic and integrated approaches that address both CMM and depression to enhance health outcomes and mitigate the reciprocal impact of these conditions among middle-aged and older populations.

ACKNOWLEDGMENTS The authors thank all team members who have contributed to CHARLS, KLoSA, HRS, ELSA, and SHARE. This analysis uses data or information from the harmonized CHARLS, KLoSA, HRS, ELSA, and SHARE data sets and Codebooks developed by the Gateway to Global Aging Data and supported by the National Institute on Aging.

FUNDING SUPPORT AND AUTHOR DISCLOSURES

Dr Xu was supported by the Hundred Talents Program Research Initiation Fund from Zhejiang University and the Fundamental Research Funds for the Central Universities. Mr Kivimäki was supported by the Wellcome Trust (grant 221854/Z/20/Z), the UK Medical Research Council (grant MR/S011676/1 and MR/R024227/1), the National Institute on Aging (grant R01AG056477), and the Academy of Finland (grant 350426). The funder of the study had no role in study design, data collection, data analysis, data interpretation, or the writing of the manuscript. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

ADDRESS FOR CORRESPONDENCE: Dr Xiaolin Xu, School of Public Health, The Second Affiliated Hospital, Zhejiang University School of Medicine, Yuhangtang Road 866, Hangzhou, Zhejiang 310058, China. E-mail: xiaolin.xu@zju.edu.cn.

PERSPECTIVES

COMPETENCY IN MEDICAL KNOWLEDGE: CMM and depression were bidirectionally associated, and the mediated effects of lifestyle factors were larger in the depression-lifestyle-CMM pathway than in the CMM-lifestyle-depression pathway.

TRANSLATIONAL OUTLOOK: Our findings underscore the importance of holistic and integrated approaches that address both CMM and depression to enhance health outcomes and mitigate the reciprocal impact of these conditions.

REFERENCES

1. Kessler RC, Bromet EJ. The epidemiology of depression across cultures. *Annu Rev Public Health*. 2013;34:119-138. https://doi.org/10.1146/annurev-publhealth-031912-114409

2. Almeida OP. Prevention of depression in older age. *Maturitas*. 2014;79(2):136-141. https://doi. org/10.1016/j.maturitas.2014.03.005

3. World Health Organization. Depression and Other Common Mental Disorders. January 2017. Accessed 14 May 2024. https://www.who.int/ publications/i/item/depression-global-healthestimates

4. Olver JS, Hopwood MJ. Depression and physical illness. *Med J Aust*. 2013;199(S6):S9–S12.

5. Khalfan AF, Campisi SC, Lo RF, McCrindle BW, Korczak DJ. The association between adolescent depression and dyslipidemia. *J Affect Disord*. 2023;338:239-245. https://doi.org/10.1016/j.jad. 2023.06.017

6. Dickens C, Jackson J, Tomenson B, Hay E, Creed F. Association of depression and rheumatoid arthritis. *Psychosomatics*. 2003;44(3):209–215.

7. Frank P, Batty GD, Pentti J, et al. Association between depression and physical conditions

requiring hospitalization. *JAMA Psychiatry*. 2023;80(7):690-699.

8. Chen Y, Shi L, Zheng X, et al. Patterns and determinants of multimorbidity in older adults: study in health-ecological perspective. *Int J Environ Res Public Health*. 2022;19(24):16756. https://doi.org/ 10.3390/ijerph192416756

9. Busija L, Lim K, Szoeke C, Sanders KM, McCabe MP. Do replicable profiles of multimorbidity exist? Systematic review and synthesis. *Eur J Epidemiol.* 2019;34(11):1025-1053. https:// doi.org/10.1007/s10654-019-00568-5 **10.** Lyall DM, Celis-Morales CA, Anderson J, et al. Associations between single and multiple cardiometabolic diseases and cognitive abilities in 474 129 UK Biobank participants. *Eur Heart J.* 2017;38(8): 577-583. https://doi.org/10.1093/eurheartj/ehw528

11. Fishbook BN, Brinton CD, Siever J, Klassen TD, Sakakibara BM. Cardiometabolic multimorbidity and activity limitation: a cross-sectional study of adults using the Canadian Longitudinal Study on Aging data. Fam Pract. 2022;39(3):455-463. https://doi.org/10.1093/fampra/cmab129

12. Ditmars HL, Logue MW, Toomey R, et al. Associations between depression and cardiometabolic health: a 27-year longitudinal study. *Psychol Med.* 2022;52(14):3007-3017. https://doi. org/10.1017/S003329172000505X

 Cheng X, Ouyang F, Ma T, et al. The individual and joint associations of depression and sleep duration with cardiometabolic diseases and mortality: a prospective cohort study. *Atherosclerosis*. 2022;361:10–17. https://doi.org/10.1016/j.atherosclerosis.2022.09.016

14. Qiao Y, Ding Y, Li G, Lu Y, Li S, Ke C. Role of depression in the development of cardiometabolic multimorbidity: findings from the UK Biobank study. J Affect Disord. 2022;319:260-266. https://doi.org/10.1016/j.jad.2022.09.084

15. Wium-Andersen IK, Osler M, Jørgensen MB, Rungby Jr, Wium-Andersen MK. Diabetes, antidiabetic medications and risk of depression—a population-based cohort and nested case-control study. *Psychoneuroendocrinology*. 2022;140:105715. https://doi.org/10.1016/j.psyneuen.2022.105715

16. Allan LM, Rowan EN, Thomas AJ, Polvikoski TM, O'Brien JT, Kalaria RN. Long-term incidence of depression and predictors of depressive symptoms in older stroke survivors. *Br J Psychiatry*. 2013;203(6):453-460. https://doi.org/ 10.1192/bjp.bp.113.128355

17. Wium-Andersen MK, Wium-Andersen IK, Prescott EIB, Overvad K, Jørgensen MB, Osler M. An attempt to explain the bidirectional association between ischaemic heart disease, stroke and depression: a cohort and meta-analytic approach. *Br J Psychiatry*. 2020;217(2):434-441. https://doi.org/10.1192/bjp.2019.130

18. Han Y, Hu Y, Yu C, et al. Lifestyle, cardiometabolic disease, and multimorbidity in a prospective Chinese study. *Eur Heart J.* 2021;42(34):3374-3384. https://doi.org/10.1093/ eurheartj/ehab413

19. Sarris J, Thomson R, Hargraves F, et al. Multiple lifestyle factors and depressed mood: a cross-sectional and longitudinal analysis of the UK Biobank (N = 84,860). *BMC Med*. 2020;18(1):354. https://doi.org/10.1186/s12916-020-01813-5

20. Thornicroft G, Ahuja S, Barber S, et al. Integrated care for people with long-term mental and physical health conditions in low-income and middle-income countries. *Lancet Psychiatry*. 2019;6(2):174-186. https://doi.org/10.1016/ S2215-0366(18)30298-0

21. Lee J, Phillips D, Wilkens J. Gateway to Global Aging Data: resources for cross-national comparisons of family, social environment, and healthy aging. J Gerontol B Psychol Sci Soc Sci. 2021;76(suppl 1):S5-S16. https://doi.org/10.1093/ geronb/gbab050

22. Sonnega A, Faul JD, Ofstedal MB, Langa KM, Phillips JWR, Weir DR. Cohort profile: the Health and Retirement Study (HRS). *Int J Epidemiol.* 2014;43(2):576-585. https://doi.org/10.1093/ije/ dyu067

23. Steptoe A, Breeze E, Banks J, Nazroo J. Cohort profile: the English Longitudinal Study of Ageing. *Int J Epidemiol.* 2013;42(6):1640-1648. https:// doi.org/10.1093/ije/dys168

24. Zhao Y, Hu Y, Smith JP, Strauss J, Yang G. Cohort profile: the China Health and Retirement Longitudinal Study (CHARLS). *Int J Epidemiol*. 2014;43(1): 61-68. https://doi.org/10.1093/ije/dys203

25. Börsch-Supan A, Brandt M, Hunkler C, et al. Data resource profile: the Survey of Health, Ageing and Retirement in Europe (SHARE). *Int J Epidemiol.* 2013;42(4):992-1001. https://doi.org/ 10.1093/ije/dyt088

26. Shin C. Korean Longitudinal Study of Ageing. In: Gu D, Dupre ME, eds. *Encyclopedia of Gerontology and Population Aging*. Springer International Publishing; 2019:1–4.

27. Xu X, Mishra GD, Dobson AJ, Jones M. Progression of diabetes, heart disease, and stroke multimorbidity in middle-aged women: a 20-year cohort study. *PLoS Med.* 2018;15(3):e1002516. https://doi.org/10.1371/journal.pmed.1002516

28. Wingo TS, Gerasimov ES, Canon SM, Lah JJ, Levey AI, Wingo AP. Alzheimer's disease genetic burden is associated with mid-life depression among persons with normal cognition. *Alzheimers Dement*. 2023;19(3):868–874. https://doi.org/10. 1002/alz.12716

29. Frank P, Kaushal A, Poole L, Lawes S, Chalder T, Cadar D. Systemic low-grade inflammation and subsequent depressive symptoms: is there a mediating role of physical activity? *Brain Behav Immun.* 2019;80:688-696. https://doi.org/10.1016/j.bbi.2019.05.017

30. Hamer M, Batty GD, Kivimaki M. Risk of future depression in people who are obese but metabolically healthy: the English Longitudinal Study of Ageing. *Mol Psychiatry*. 2012;17(9):940–945. https://doi.org/10.1038/mp.2012.30

31. López-Bueno R, Calatayud J, Andersen LL, et al. Dose-response association of handgrip strength and risk of depression: a longitudinal study of 115 601 older adults from 24 countries. *Br J Psychiatry*. 2023;222(3):135–142. https://doi.org/ 10.1192/bjp.2022.178

32. Prince MJ, Reischies F, Beekman ATF, et al. Development of the EURO-D scale—a European Union initiative to compare symptoms of depression in 14 European centres. *Br J Psychiatry*. 1999;174(4):330–338. https://doi.org/10. 1192/bjp.174.4.330

33. Ng CD, Weiss J. Association of genetic and behavioral characteristics with the onset of diabetes. *BMC Public Health.* 2019;19(1):1297. https://doi.org/10.1186/s12889-019-7618-z

34. Lasserre AM, Strippoli MPF, Glaus J, et al. Prospective associations of depression subtypes with cardio-metabolic risk factors in the general population. *Mol Psychiatry*. 2017;22(7):1026-1034. https://doi.org/10.1038/mp.2016.178

35. Armstrong NM, Meoni LA, Carlson MC, et al. Cardiovascular risk factors and risk of incident depression throughout adulthood among men: the Johns Hopkins Precursors Study. J Affect Disord. 2017;214:60–66. https://doi.org/10.1016/ ijad.2017.03.004

36. Newberg AR, Davydow DS, Lee HB. Cerebrovascular disease basis of depression: post-stroke depression and vascular depression. *Int Rev Psychiatry*. 2006;18(5):433-441.

37. van Sloten TT, Sedaghat S, Carnethon MR, Launer LJ, Stehouwer CDA. Cerebral microvascular complications of type 2 diabetes: stroke, cognitive dysfunction, and depression. *Lancet Diabetes Endocrinol*. 2020;8(4):325–336. https://doi.org/ 10.1016/52213-8587(19)30405-X

38. Tabák AG, Akbaraly TN, Batty GD, Kivimäki M. Depression and type 2 diabetes: a causal association? Lancet Diabetes Endocrinol. 2014;2(3):236-245. https://doi.org/10.1016/S2213-8587(13)70139-6

39. Robinson RG, Jorge RE. Post-stroke depression: a review. *Am J Psychiatry*. 2016;173(3):221-231. https://doi.org/10.1176/appi.ajp.2015.15030363

40. Bruce DG, Casey G, Davis WA, et al. Vascular depression in older people with diabetes. *Diabetologia*. 2006;49(12):2828-2836.

41. Hare DL, Toukhsati SR, Johansson P, Jaarsma T. Depression and cardiovascular disease: a clinical review. *Eur Heart J.* 2014;35(21):1365-1372. https://doi.org/10.1093/eurheartj/eht462

42. Kyrou I, Tsigos C. Stress hormones: physiological stress and regulation of metabolism. *Curr Opin Pharmacol.* 2009;9(6):787-793. https://doi.org/10.1016/j.coph.2009.08.007

43. Kivimäki M, Bartolomucci A, Kawachi I. The multiple roles of life stress in metabolic disorders. *Nat Rev Endocrinol.* 2023;19(1):10-27. https://doi.org/10.1038/s41574-022-00746-8

44. Chrousos GP. Stress and disorders of the stress system. *Nat Rev Endocrinol*. 2009;5(7):374-381. https://doi.org/10.1038/nrendo.2009.106

45. Herbert J, Goodyer IM, Grossman AB, et al. Do corticosteroids damage the brain? *J Neuroendocrinol*. 2006;18(6):393-411.

46. Moulton CD, Costafreda SG, Horton P, Ismail K, Fu CHY. Meta-analyses of structural regional cerebral effects in type 1 and type 2 diabetes. *Brain Imaging Behav.* 2015;9(4):651-662. https://doi.org/10.1007/s11682-014-9348-2

47. Launders N, Kirsh L, Osborn DPJ, Hayes JF. The temporal relationship between severe mental illness diagnosis and chronic physical comorbidity: a UK primary care cohort study of disease burden over 10 years. *Lancet Psychiatry*. 2022;9(9):725-735. https://doi.org/10.1016/S2215-0366(22)00225-5

48. Gilsanz P, Walter S, Tchetgen Tchetgen EJ, et al. Changes in depressive symptoms and incidence of first stroke among middle-aged and older US adults. *J Am Heart Assoc.* 2015;4(5):e001923. https://doi.org/10.1161/JAHA.115.001923

49. Ratliff S, Mezuk B. Depressive symptoms, psychiatric medication use, and risk of type 2 diabetes: results from the Health and Retirement Study. *Gen*

671

Hosp Psychiatry. 2015;37(5):420-426. https://doi. org/10.1016/j.genhosppsych.2015.05.008

50. Pierce MB, Zaninotto P, Steel N, Mindell J. Undiagnosed diabetes—data from the English Longitudinal Study of Ageing. *Diabet Med.* 2009;26(7):679-685. https://doi.org/10.1111/j. 1464-5491.2009.02755.x

51. Xiaojing Y, Tingting L, Lang W, Zhi-Yong Z, Changwei L. Validity of self-reported diabetes among middle-aged and older Chinese adults: the China Health and Retirement Longitudinal Study. *BMJ Open.* 2015;5(4):e006633. https://doi.org/10.1136/bmiopen-2014-006633

52. Andresen EM, Malmgren JA, Carter WB, Patrick DL. Screening for depression in well older adults: evaluation of a short form of the CES-D (Center for Epidemiologic Studies Depression Scale). *Am J Prev Med.* 1994;10(2):77-84.

53. Prince MJ, Reischies F, Beekman AT, et al. Development of the EURO-D scale—a European Union initiative to compare symptoms of depression in 14 European centres. *Br J Psychiatry*. 1999;174:330–338.

54. Boey KW. Cross-validation of a short form of the CES-D in Chinese elderly. *Int J Geriatr Psychiatry*. 1999;14(8):608–617.

55. Kessler RC, Ustün TB. The World Mental Health (WMH) Survey Initiative Version of the World Health Organization (WHO) Composite International Diagnostic Interview (CIDI). Int J Methods Psychiatr Res. 2004;13(2): 93-121.

56. Díaz-Mardomingo MDC, García-Herranz S, Rodríguez-Fernández R, Venero C, Peraita H. Problems in classifying mild cognitive impairment (MCI): one or multiple syndromes? *Brain Sci.* 2017;7(9):111. https://doi.org/10.3390/brainsci7090111

57. Jak AJ, Preis SR, Beiser AS, et al. Neuropsychological Criteria for Mild Cognitive Impairment and Dementia Risk in the Framingham Heart Study. J Int Neuropsychol Soc. 2016;22(9):937-943.

KEY WORDS cardiovascular diseases, diabetes, lifestyle modifications, mental health, reciprocal relationship

APPENDIX For supplemental methods, tables, and figures, please see the online version of this paper.